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The enzyme 11-beta-hydroxysteroid dehydrogenase isoenzyme 2 (11BHSD2) is 24 
responsible for converting the active glucocorticoid cortisol to inactive cortisone and 25 
in the renal medulla protects the mineralocorticoid receptor (MR) from activation by 26 
cortisol. Derangements in 11BHSD2 activity can result in reduced conversion of 27 
cortisol to cortisone, activation of the MR by cortisol and, consequently, sodium and 28 
water retention. The objective of this study was to examine glucocorticoid 29 
metabolism in canine congestive heart failure (CHF), specifically to evaluate whether 30 
renal 11BHSD2 activity and expression were altered. Dogs were prospectively 31 
recruited into one of two phases; the first phase (n = 56) utilized gas 32 
chromatography-tandem mass spectrometry to examine steroid hormone 33 
metabolites normalised to creatinine in home-caught urine samples. Total serum 34 
cortisol was also evaluated. The second phase consisted of dogs (n = 18) 35 
euthanased for refractory CHF or behavioural reasons. Tissue was collected from 36 
the renal medulla for examination by quantitative reverse transcription polymerase 37 
chain reaction, immunohistochemistry and protein immune-blotting. Heart failure did 38 
not change urinary cortisol:cortisone ratio (P = 0.388), or modify renal expression (P 39 
= 0.303), translation (P = 0.427) or distribution of 11BHSD2 (P = 0.325). However, 40 
CHF did increase excretion of 5α-tetrahydrocortisone (P = 0.004), α-cortol (P = 41 
0.002) and α-cortolone (P = 0.009).  Congestive heart failure modifies glucocorticoid 42 
metabolism in dogs by increasing 5α-reductase and 20α-hydroxysteroid 43 
dehydrogenase activity. Differences between groups in age, sex and underlying 44 
disease processes may have influenced these results. However, 11BHSD2 does not 45 
appear to be a potential therapeutic target in canine CHF.  46 




 Introduction 49 
Congestive heart failure (CHF) in dogs is a common sequel to cardiac diseases, 50 
such as myxomatous mitral valve disease (MMVD), and the neurohumoral and 51 
haemodynamic consequences (Egenvall et al., 2005). Treatment of CHF is 52 
multifaceted, but a cornerstone of its management is antagonism of the renin-53 
angiotensin-aldosterone system (RAAS). Activation of the RAAS results in, amongst 54 
many other effects, increased cardiac afterload together with sodium and water 55 
retention by upregulating angiotensin II and aldosterone expression (Ames et al., 56 
2019). The effects of aldosterone can be antagonised at the level of the distal 57 
nephron with mineralocorticoid receptor (MR) antagonists such as spironolactone. 58 
These antagonists prevent sodium and potassium exchange within the renal 59 
collecting duct, thereby, reducing the excess sodium and water retention that 60 
contributes to volume overload. However, despite combining spironolactone with 61 
other successful therapeutic agents such as diuretics, pimobendan and angiotensin 62 
converting enzyme inhibitors, there is usually progression to end-stage CHF (Group, 63 
1999; Haggstrom et al., 2008). Therefore, there is need to understand the 64 
mechanisms that contribute to further sodium and water retention, even in the face of 65 
RAAS antagonism, so that new treatment strategies targeting these pathways can 66 
be developed.     67 
The enzyme 11 beta-hydroxysteroid dehydrogenase isoenzyme 2 (11BHSD2) is of 68 
interest because it co-localises with the MR in the distal nephron (Krozowski et al., 69 
1995; Kyossev et al., 1996). The MR has a high affinity for cortisol as well as 70 
aldosterone; by converting cortisol to inactive cortisone, 11BHSD2 reduces cortisol 71 
mediated sodium and water retention (Funder et al., 1988). 11BHSD2 activity can be 72 
deduced from the urinary cortisol to cortisone ratio (Best and Walker, 1997). By 73 
 
 
contrast, the enzyme 11BHSD1, which is ubiquitously distributed throughout the 74 
body, can increase the availability of cortisol by reactivation of cortisone to cortisol 75 
(Jamieson et al., 2000). The overall balance between 11BHSD1 and 11BHSD2 76 
activity can be quantified by determining the ratios of urinary glucocorticoid 77 
metabolites that result from hepatic breakdown of cortisol and cortisone by A-ring 5α- 78 
and 5β-reductases (Boonen et al., 2013; Vantyghem et al., 1998) (Fig. 1).  79 
In human subjects, congenital or acquired impairment of 11BHSD2 activity results in 80 
the syndrome of apparent mineralocorticoid excess, expanding vascular volume and 81 
causing systemic hypertension, suppressed renin concentration and hypokalaemia 82 
(Funder, 2017). Mineralocorticoid receptor antagonists, such as spironolactone or 83 
eplerenone, are used to prevent activation of the MR by cortisol in these patients.  84 
The aim of this study was to investigate whether CHF in dogs is associated with a 85 
reduction in renal 11BHSD2 activity. Gas chromatography-tandem mass 86 
spectrometry (GC-MS/MS) was used to examine the urinary steroid profile in dogs 87 
with and without naturally occurring CHF, and to calculate enzymatic activity within 88 
the glucocorticoid metabolic pathway. The effect of CHF on tissue gene and protein 89 
expression for 11BHSD2 was determined using quantitative reverse transcription 90 
polymerase chain reaction (RT-qPCR) and protein immuno-blotting (Western). 91 
 92 
Materials and Methods 93 
Ethical approval was granted on 14th February 2014 by The University of 94 
Edinburgh’s Veterinary Ethical Review Committee, VERC 0814.  95 
Steroid profiling in urine and serum 96 
 
 
Dogs were prospectively recruited from the referral and first opinion populations of 97 
the Royal (Dick) School of Veterinary Studies between June 2014 and August 2016.  98 
All dogs underwent a complete physical examination by a board-certified cardiologist 99 
or resident in training under their supervision, and were divided into five groups; 100 
healthy control (dogs owned by staff or students that were physically normal and not 101 
receiving medication), chronic disease without heart disease (CD), International 102 
Small Animal Cardiac Health Council (ISACHC) class I (cardiac disease without 103 
clinical signs), ISACHC class II (advanced cardiac disease with mild or controlled 104 
CHF) without spironolactone (CHF-S) and ISACHC class II with spironolactone 105 
(CHF+S). Dogs not in the control group underwent complete cardiac evaluation 106 
including haematology, biochemistry, echocardiography (Vivid-7, GE), 107 
electrocardiography (AT-102 Plus, Schiller) and blood pressure measurement 108 
(Cardell 9402, Midmark). Additional diagnostic tests, such as thoracic radiography or 109 
computed tomography, were performed according to clinical need. Dogs were 110 
excluded if they were under six months of age, if they had systemic illnesses that 111 
potentially affected cardiovascular function, such as pre-existing renal disease 112 
(defined as blood creatinine >125 µmol/L and evidence of renal disease based on 113 
imaging, where available), or if they had received glucocorticoids in the previous six 114 
months. Dogs with respiratory disease were included in the CD group unless there 115 
was evidence of pulmonary hypertension on echocardiography (tricuspid 116 
regurgitation >2.8 m/s or pulmonic insufficiency of >2.2m/s (Rudski et al., 2010)).  117 
Blood samples were obtained by jugular venepuncture in all dogs, apart from 118 
controls, shortly after presentation. Samples were centrifuged within an hour of 119 
collection at 850g for five minutes and serum separated, and batch stored at -80 °C 120 
until use (maximum six months). Total serum cortisol concentration was analysed by 121 
 
 
a chemiluminescent immunoassay (Immulite 1000, Siemens) according to the 122 
manufacturer’s instructions.  123 
Urine samples (free catch, mid-flow, at home, minimum 15mL) were collected by 124 
owners on the morning of presentation for all dogs. Urine was stored at -80 °C 125 
(maximum six months) before batch analysis of urinary cortisol metabolites and 126 
creatinine.  127 
Urinary GC-MS/MS analysis 128 
The steroid profile of urine samples was determined by GC-MS/MS (Andrews et al., 129 
2002; Best and Walker, 1997) and adapted for tandem mass spectrometry (Homer et 130 
al., 2017; Boag et al., 2020).  Briefly, steroids were enriched with internal standards 131 
and extracted from 15 – 20 mL of urine through Sep-Pak C18 cartridges (Waters, 132 
UK), hydrolysed with β-glucuronidase (Sigma), followed by formation of the 133 
methoxime-trimethylsilyl derivatives (Sigma) (Best and Walker, 1997). This was 134 
followed by gas chromatography (GC) separation and mass analysis on a TSQ 135 
Quantum Ultra GC using triple quadrupole mass spectrometer (Thermo Scientific). 136 
Steroid extracts were analysed along with calibration standards.   137 
The GC-MS/MS method measured cortisol (F), cortisone (E), 5β-tetrahydrocortisol 138 
(5βTHF), 5α-tetrahydrocortisol (5αTHF), 5β-tetrahydrocortisone (5βTHE), 5α-139 
tetrahydrocortisone (5αTHE), α-cortol, β-cortol, α-cortolone and β-cortolone (Homer 140 
et al., 2017). 141 
Creatinine was used to standardise concentrations of steroid metabolites due to 142 
variations in volume and concentration of urine between samples. Creatinine was 143 
determined using the creatininase/creatinase specific enzymatic method utilising a 144 
commercial kit (Alpha Laboratories Ltd.) adapted for use on a Cobas Fara centrifugal 145 
 
 
analyser (Roche Diagnostics Ltd) (Borner et al., 1979). Steroid hormone 146 
concentration per litre (µg/L) was indexed to creatinine (g/L).  147 
Ratios of urinary steroid metabolites were derived to investigate activity of various 148 
enzymes important to the cortisol/cortisone metabolic pathway. Urinary cortisol to 149 
cortisone ratio (F/E) was used to infer renal 11βHSD2 activity (Best and Walker, 150 
1997; Boonen et al., 2013), and whole-body 11βHSD balance was determined using 151 
the ratio of (5αTHF+5βTHF)/(5βTHE+5αTHE), modified from the human urinary 152 
steroid method, by the addition of 5αTHE to account for the higher levels in dogs 153 
compared to humans (Boonen et al., 2013; Vantyghem et al., 1998). Alpha- and 154 
beta-reductases irreversibly metabolise cortisol and cortisone, and their relative 155 
activities were estimated by the 5βTHF/5αTHF ratio (Boonen et al., 2013). Total A-156 
ring reduction of cortisol was estimated by the (5αTHF+5βTHF)/F ratio. Total cortisol 157 
metabolite excretion per kg bodyweight was determined by summing 5αTHF, 158 
5βTHF, 5βTHE, 5αTHE, cortols and cortolones. 159 
11BHSD2 kidney gene and protein expression 160 
A separate group of dogs was prospectively recruited for this part of the study and 161 
included dogs euthanased (intravenous pentobarbitone over-dose (Animalcare, UK)) 162 
due to refractory CHF (ISACHC stage IIIa/b) and healthy dogs (control), not on 163 
medications euthanased for behavioural reasons. The CHF dogs underwent a 164 
physical examination, haematology, biochemistry, echocardiography, 165 
electrocardiography, thoracic radiography and blood pressure measurement. 166 
Controls received only a physical examination. Exclusion criteria were as before.  167 
The left kidney was removed within 30 minutes of euthanasia and examined for any 168 
gross pathological abnormalities, if any were present the animal was excluded. The 169 
 
 
renal medulla and cortex were removed by sharp dissection, transversely sectioned 170 
and samples of each were then fixed in 10% formalin for a minimum of 48 hours 171 
(then paraffin wax embedded for histopathology and immunofluorescence), snap-172 
frozen in dry-ice (then stored at -80 °C for a maximum of six months for Western 173 
blots) or stored in RNAlater (Ambion, UK; 4 °C for 24 hours then -20 °C for a 174 
maximum of six months for quantitative real-time PCR).  The left adrenal gland was 175 
also removed and prepared, as for the renal medulla and cortex, for 176 
immunohistochemistry only.  177 
Total RNA and qPCR 178 
Total RNA was isolated from 50-80 mg samples of renal medulla, cDNA synthesised 179 
and real-time qPCR experiments were performed by standard technique, as 180 
previously described (Cartwright et al., 2018). Further details can be found in 181 
Supplementary material.  182 
Melting curve analysis was performed for reference (glyceraldehyde 3-phosphate 183 
dehydrogenase (GAPDH) and mitochondrial 28S ribosomal protein subunit 25 184 
(MRPS25) and target gene (11BHSD2). Primers were obtained from Eurofins 185 
Genomics (Ebersburg) and designed using the Roche primer design software based 186 
on Canis familiaris sequences from the Ensembl database. The Basic Local 187 
Alignment Search Tool (National Center for Biotechnology Information) was utilised 188 
to confirm gene specificity. Primer sequences are shown in Table 1. Primer 189 
efficiencies were between 92 and 99%. All PCR reactions exhibited one well-defined 190 
melting curve peak. Relative expression levels were normalised to the reference 191 
genes and calculated using the 2-ΔΔCt method (Livak and Schmittgen, 2001).  192 
Western blots 193 
 
 
Samples were thawed on ice and suspended in radioimmunoprecipitation assay 194 
buffer (RIPA; Roche). Protein concentrations were determined using the Bio-Rad 195 
protein detergent-compatible assay (Bio-Rad). 15 µg of protein was separated using 196 
a 10% Bis-Tris gel (Thermo Fisher Scientific), transferred to a nitrocellulose 197 
membrane, and probed with goat anti-human 11BHSD2 antibody (1:300, reactivity 198 
with Canis lupus familiaris, Santa Cruz Biotechnology) and a fluorescent donkey 199 
anti-goat secondary antibody (1:800, LI-COR Biosciences). Membranes were 200 
stripped and re-probed with a primary β-actin antibody (1:1000, Santa Cruz 201 
Biotechnology) used as a loading control followed by a fluorescent donkey anti-rabbit 202 
secondary antibody (1:800, LI-COR Biosciences).  Bound antibody was detected 203 
with a LI-COR Odyssey scanner according to the manufacturer recommendations. 204 
Densitometry analysis of protein was performed using LI-COR Image Studio 205 
software (Eaton et al., 2013). 206 
Immunofluorescent staining and imaging 207 
Immunofluorescent staining was performed on renal medulla, renal cortex and 208 
adrenal gland (positive tissue control). Detailed methods can be found in 209 
Supplementary materials. Polyclonal IgG primary antibodies against 11BHSD2 and 210 
nephrin (positive control; Santa Cruz Biotechnology, Germany) were utilised, diluted 211 
in 2.5% normal horse serum (Vector Laboratories) (11βHSD2 1:200 dilution, nephrin 212 
1:100). The secondary antibody was horse anti-goat IgG (Ready-to-use Vectafluor 213 
Dylight-594; Vector Laboratories). Nuclei were counterstained with 4’,6-diamidino-2-214 
phenylindole (DAPI; Prolong Gold, Life Technologies). Further details can be found 215 
in Supplementary material. 216 
 
 
Fluorescent images were captured using blue (10 m/s exposure) and green (400 m/s 217 
exposure) fluorescent filters (Leica-DMLB; Leica) and examined blindly by a single 218 
author (GRM). Five images were taken at x20 magnification per slide. Image 219 
analysis software (Photoshop CC, Adobe) was used to examine the relative degree 220 
of staining of the inner medulla for 11BHSD2 positive cells in CHF and control 221 
animals. The number of stained pixels was identified and compared to the total 222 
number of pixels within the image to give a percentage staining.  223 
 224 
Statistics 225 
Sigmaplot 13.0 (Systat Software Inc.) was used for all statistical analysis. All data 226 
were tested for normality with the Shapiro-Wilk test and were expressed as mean ± 227 
standard deviation (normal) or median with inter-quartile range (IQR; non-normal). 228 
Differences in sex between groups was examined using the chi-square test. Multiple 229 
comparisons used one-way ANOVA with Tukey post hoc tests or Kruskal-Wallis with 230 
Dunns pairwise multiple comparison tests according to normality and equality of 231 
variance of residuals. A P-value <0.05 was considered significant.  232 
 233 
Results 234 
Dog population 235 
A total of 56 dogs (Table 2) were recruited for the steroid profiling study comprising 236 
14 control dogs, 14 CD dogs, seven ISACHC-I dogs, 10 CHF-S dogs and nine 237 
CHF+S dogs. There was no difference in age (P=0.79) or sex (P=0.66) between 238 
groups. The most frequently identified diseases within each group were as follows; 239 
 
 
CD, 4/14 pulmonary adenocarcinoma (29%); ISACHC-I, 5/7 MMVD (71%); CHF-S, 240 
MMVD 4/10 (40%) and dilated cardiomyopathy (DCM) 4/10 (40%); CHF+S, 5/9 241 
MMVD (56%).  242 
Eighteen dogs were recruited for the 11BHSD2 expression study, comprising nine 243 
CHF and nine control dogs (Table 2). There was no difference in age (P=0.98) or sex 244 
(P=0.49) between groups. The most commonly identified underlying disease in the 245 
CHF group was DCM 7/9 (78%).  246 
Prescribed treatments are outlined in Table 2 for both studies. 247 
Total serum cortisol and urinary steroid metabolites 248 
There was no statistically significant difference in total serum cortisol between 249 
groups (median (IQR); CD 103.1 µg/g (52.8-176.6); ISACHC-I 54.6 µg/g (46.9-82.5); 250 
CHF-S 92.0 µg/g (46.8-121.8); CHF+S 79.5 µg/g (54.9-138.5), P=0.42). Alpha-cortol 251 
was below the detection limit of the assay in the urine of 3/14 control dogs, 6/14 CD 252 
dogs, 2/7 ISACHC-I dogs, 2/10 CHF–S and 4/9 CHF+S, as was urinary cortisol in 253 
one CHF+S dog.  254 
There was no significant difference in urinary cortisol or cortisone between the 255 
groups (Fig. 2a and b). There were significant differences in other urinary steroid 256 
metabolites, and the details are illustrated in figure 2. 5α-tetrahydrocortisone was 257 
increased in CHF-S (P=0.021) and CHF+S (P=0.032) compared to dogs with CD 258 
(Fig. 2d). Dogs with CHF+S had increased levels of α-cortol (Fig. 2h) compared to 259 
control (P=0.030) and CD (P=0.045). Dogs with CHF-S also had increased levels of 260 
α-cortol compared to dogs in the control (P=0.028) or CD (P=0.048) groups. Alpha-261 
cortolone was different between groups (P=0.009), although there was no statistical 262 
 
 
significance following post hoc analysis (Fig. 2g). Total cortisol metabolite excretion 263 
was not different between groups (Fig. 2k). 264 
Activity of steroid metabolising enzymes 265 
There was no difference in renal 11BHSD2 activity, as inferred by the F/E ratio (Fig. 266 
3a, P=0.388), whole body 11BHSD balance (Fig. 3b, P=0.644), total A-ring reduction 267 
(Fig. 3c, P=0.294) or in relative activity of 5α- and 5β-reductases (Fig. 3d, P=0.199).  268 
11BHSD2 mRNA and protein levels in control dogs and those with heart failure 269 
11BHSD2 gene expression was identified in the renal medulla in both control and 270 
CHF groups, but there was no difference in the level of gene expression between 271 
groups (P=0.303). 272 
The 11BHSD2 protein was found in all renal medulla samples, but there was no 273 
difference in expression levels between CHF and control (Fig. 4; P=0.427).  274 
Immunofluorescent analysis of 11BHSD2 protein expression in the renal 275 
medulla   276 
Positive staining for 11BHSD2 was identified in all sections of the renal medulla and 277 
cortex (Fig. 5ai and 5aii). In the renal cortex no staining was identified in the 278 
glomeruli and proximal convoluted tubule (Fig. 5ai). There was no significant 279 
difference in the staining for 11BHSD2 in the renal medulla comparing CHF and 280 





This study demonstrates that in dogs with CHF, with or without pharmacological 284 
blockade of the MR, there is modified metabolism of cortisol. However, contrary to 285 
our hypothesis, there is no reduction in 11BHSD2 activity. Instead, there is increased 286 
levels of α-cortol and cortolone in CHF, resulting from increased 20-α-hydroxysteroid 287 
dehydrogenase activity (Fig 1). The increase in 5α-THE represents a shift in 5α 288 
reduction over 5β reduction. This finding suggests that changes to cortisol 289 
metabolism are mild in CHF dogs and do not contribute to sodium and water 290 
retention via the MR.   291 
A previous study had investigated plasma concentrations and urinary excretion of 292 
cortisol in dogs with pre-clinical and clinical DCM, and similar to the current study, 293 
total serum cortisol levels were not different and could not distinguish between the 294 
two groups (Tidholm et al., 2005). Serum cortisol exists in free and bound to cortisol-295 
binding globulin forms (Westphal, 1967). In the current study, free and protein-bound 296 
fractions were not measured to determine sensitivity of either to detect CHF. Instead, 297 
cortisol and its urinary metabolites were measured by GC-MS/MS, as this provides 298 
more information on the exposure of MR to inappropriate activation by cortisol than 299 
circulating cortisol (Best and Walker, 1997).  300 
While there was a trend towards increased urinary cortisol in dogs in CHF prior to 301 
spironolactone therapy, this did not achieve statistical significance, probably due to 302 
the wide variation in the data. Markedly increased urinary cortisol has been 303 
described in dogs with clinical DCM (Tidholm et al., 2005). While the range of breeds 304 
and cardiac diseases in the current study may have been a factor in the variability of 305 
the data, it does suggest that in the general dog population urinary cortisol is not an 306 
effective biomarker for CHF. Furthermore, unlike the study in DCM dogs, GC-MS/MS 307 
was used, as it is the gold standard analytical approach, instead of 308 
 
 
radioimunnoassays which can cross-react with cortisol metabolites (Lindberg et al., 309 
1982; Tidholm et al., 2005). The current study has quantified the effects of CHF on 310 
cortisol (Fig. 2), its metabolites (Fig. 2) and the activity of associated enzymes (Fig. 311 
3), and has demonstrated that CHF increases some of these metabolites.   312 
The effects of chronic disease states, the stress of which can increase the variation 313 
in urinary cortisol concentrations, were separated from the effects of CHF by 314 
including two additional groups. While this increased the possibility of a Type II error 315 
it did improve the potential clinical utility of the study. Stress effects were also limited 316 
by only analysing home-caught urine samples.  317 
Our data show that dogs in CHF have increased levels of α-cortol and α-cortolone 318 
and so increased 20αHSD activity (Fig. 1 and 2). The final product of this enzyme, 319 
the α-cortols and α-cortolones, are produced in a number of tissues including 320 
reproductive organs, the adrenal gland, thymus, brain and kidney (El-Kabbani et al., 321 
2011). It is likely they do not play an important role in the pathogenesis of CHF, but 322 
are end-products of modulation of cortisol metabolism by CHF that is not seen in 323 
other chronic disease states.  324 
The MR is found in non-epithelial tissues such as cardiomyocytes, but these have 325 
very low levels of 11BHSD2 (Arriza et al., 1987; Chapman et al., 2013). Therefore, it 326 
is necessary to establish whether an increase in 11BHSD2 activity might be linked to 327 
increased renal production of 11BHSD2 or a change in its distribution within the 328 
kidney. One can speculate that the lack of influence of CHF on expression and 329 
translation of the gene encoding 11BHSD2, and similar distribution in the kidney of 330 
healthy controls indicates that any increased activity of 11BHSD2 would be minimal 331 
within the range for 11BHSD2 present in the healthy state. Whether or not the same 332 
 
 
applies to the reductase and HSD enzymes downstream of 11BHSD2 cannot be 333 
stated. The clinical usefulness of determining this is questionable since the 334 
modulation of cortisol metabolism in CHF does not appear to be maladaptive and, is 335 
unlikely to become a therapeutic target. However, it was important to determine 336 
whether there was any potentially adverse influence on cortisol metabolism during 337 
pharmacological manipulation.   338 
Spironolactone is a widely used MR antagonist in CHF cases. Although blockade of 339 
MR to reduce sodium and water retention is desirable in CHF, it could lead to 340 
accumulations of cortisol, and deleterious clinical consequences if spironolactone 341 
was suddenly withdrawn or MR blockade was incomplete. Spironolactone did appear 342 
to disrupt the trend towards increased cortisol in CHF, but there was no 343 
demonstrable influence on 11BHSD2. There was an increase in 5αTHE production 344 
(indicating increased 5α-reductase activity) when compared to the chronic disease 345 
group. However, the absence of any change to 11BHSD balance or significant 346 
increase in α-cortolone production suggests spironolactone effect on cortisol 347 
metabolism is clinically irrelevant. Similarly, renal disease in human patients treated 348 
with spironolactone do not have altered cortisol metabolite excretion or 11BHSD2 349 
activity (Hammer et al., 2010). Overall, this supports the conclusion that RAAS 350 
activation, rather than decreased renal 11BHSD2 activity, is the major contributor to 351 
sodium and water retention via MR in canine CHF.    352 
While the preferred method for evaluating urinary metabolites in people involves 24-353 
hour urine collection to adjust for diurnal variation in cortisol secretion, spot urine 354 
collection in human studies agree favourably with those from 24-hour sampling 355 
(Parikh et al., 2018). Furthermore, diurnal variation does not occur in dogs and the 356 
method used in the current study, where urine was collected prior to admission, 357 
 
 
analysis was performed on a single sample, and glucocorticoid metabolites were 358 
normalised to creatinine to account for differing glomerular filtration rates between 359 
dogs, was a valid approach (Johnston and Mather, 1978).  360 
One confounding limitation of the study was differences in drug administration 361 
between groups. This was not controlled for as it was the decision of the attending 362 
clinician to prescribe therapy depending on clinical need.   363 
 364 
Conclusions 365 
In summary, activity of the enzyme 11BHSD2 does not appear to be significantly 366 
modified in canine CHF. However, other components of the glucocorticoid metabolic 367 
pathway are modified by CHF and may contribute to prevention of inappropriate 368 
activation of MR by cortisol.   369 
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Tables  499 
 500 
Table 1: Target and reference gene primer sequences. 11BHSD2; 11 beta-501 
hydroxysteroid dehydrogenase, GAPDH; glyceraldehyde 3-phosphate 502 
dehydrogenase, MRPS25; mitochondrial ribosomal protein subunit 25.  503 
Primer Sequence (5’-3’) 
11BHSD2 Forward CACTGGAGTTCTCAAAGGCC Reverse TGCCCACAGTCACTATACGA 
GAPDH Forward AATGTATCAGTTGTGGATCTGACC Reverse GCTTCACTACCTTCTTGATGTCG 
MRPS25 Forward TCTTGGGGAAGAACAAGGAA Reverse AGTGGGCGGGTGAGAAAG 
  504 
 
 
Table 2: Population characteristics of dogs included in the in vivo and in vitro phases. ISACHC; International Small Animal Cardiac Health 505 
Council, MMVD; myxomatous mitral valve disease, DCM; dilated cardiomyopathy, PDA; patent ductus arteriosus, ME; male entire, MN; male 506 
neutered, FE; female entire, FN; female neutered, S; spironolactone, na; not applicable.  507 
 In vivo phase In vitro phase 
 Control Chronic disease ISACHC class I Heart failure-S Heart failure+S Control Heart failure 
n 14 14 7 10 9 9 9 
Age 5.7 ± 3.4 6.2 ± 3.5 7.8 ± 3.4 5.9 ± 4.1 6.6 ± 4.3 4.3 ± 1.8 (n=8) 4.2 ± 3.6 
Sex 
MN n=7, FE n=1,  
FN n=6 
ME n=1, MN n=8, 
FE n=1, FN n=4 
MN n=3, FE n=1, FN 
n=3 
MN n=4, FE n=2, 
FN n=4 
ME n=2, MN n=4, 
FE n=1, FN n=2 
ME n=4, MN n=1, 
FE n=2, FN n=1, 
Unknown n=1 
ME n=2, MN n=1, 
FE n=2, FN n=4 
Breeds 
Cross breed (n=5), 
Lurcher (n=3), 
Podenco (n=2), 1 




Labrador (n=2), 1 









breed, Shih tzu and 
Husky 
Cocker spaniel 









(n=2), Cross breed 
(n=2), Labrador 








(n=2), 1 each of 
German wire haired 
pointer, Standard 
poodle, Cross breed, 
Cairn terrier, Cocker 
spaniel 
Staffordshire bull 
terrier (n=5), 1 each 
of Akita, Pit bull 
terrier, Bullmastiff, 
Jack Russell terrier 
Flat coat retriever 
(n=2), Lurcher (n=2), 




















MMVD (n=4), DCM 
(n=4), PDA (n=1), 
tricuspid valve 
dysplasia (n=1) 
MMVD (n=5), mitral 
valve dysplasia 
(n=3), DCM (n=1) 
na DCM (n=7), mitral 
valve dysplasia 
(n=1), tricuspid valve 
dysplasia (n=1) 
Medications  

















aspirin (n=1)  









Figure legends 509 
 510 
Figure 1. A summary of the glucocorticoid metabolic pathway. The dashed lines 511 
indicate that more than one step is involved in this process. 11BHSD1; 11 beta-512 
hydroxysteroid dehydrogenase 1, 11BHSD2; 11 beta-hydroxysteroid dehydrogenase 513 
2. 514 
 515 
Figure 2. Changes in urinary glucocorticoid metabolite concentrations. Box 516 
and whisker plots showing the differences in normalised glucocorticoid metabolites 517 
between groups in ug/g. a. Cortisol. b. Cortisone. c. 5β-tetrahydrocortisone. d. 5α-518 
tetrahydrocortisone. e. 5α-tetrahydrocortisol. f. 5β-tetrahydrocortisol. g. α-cortolone. 519 
h. α-cortol. i. β-cortolone. j. β-cortol. k. Total cortisol metabolite excretion. CD; 520 
control, ISACHC; International Small Animal Cardiac Health Council, CHF; 521 
congestive heart failure, S; spironolactone, THF; tetrahydrocortisol, THE; 522 
tetrahydrocortisone.            *P <0.05. 523 
 524 
Figure 3. Changes in the relative activity of glucocorticoid metabolising 525 
enzymes.  Box and whisker plots showing the differences in the activity of 526 
glucocorticoid metabolising enzymes between groups. a. Cortisol: cortisone inferring 527 
11BHSD2 activity. b. Whole body balance of 11BHSD activity. c. Total A-ring 528 
reduction. d. relative activities of 5α and 5β reductases. CD; control, ISACHC; 529 
International Small Animal Cardiac Health Council, CHF; congestive heart failure, S; 530 
spironolactone, BHSD; beta-hydroxysteroid dehydrogenase.  531 
 
 
Figure 4. 11 Beta-hydroxysteroid dehydrogenase 2 protein levels in the renal 532 
medulla of dogs with congestive heart failure. Summary data together with 533 
representative Western blots for 11BHSD2 and B-actin for heart failure and control 534 
animals. Western blots were normalised to B-actin. PC; positive control, CHF; 535 
congestive heart failure, 11BHSD2; 11 beta-hydroxysteroid dehydrogenase 2.  536 
 537 
Figure 5. 11 Beta-hydroxysteroid dehydrogenase 2 protein expression in the 538 
renal medulla of dogs with congestive heart failure. ai. Representative cross 539 
section of renal cortex from a dog with heart failure. aii. Representative cross section 540 
of renal medulla from a dog with heart failure. b. Box and whisker plot showing no 541 
difference in percentage staining between congestive heart failure (CHF) and control 542 
groups.  543 
 544 
 545 
